Summary
DexCom, Inc. (DXCM) disclosed on March 7, 2025, that it received a warning letter from the U.S. Food and Drug Administration (FDA) on March 4, 2025, following inspections of its San Diego and Mesa facilities. The FDA cited deficiencies related to manufacturing processes and quality management systems, stemming from earlier Form 483 observations. Importantly, the company stated that this warning letter does not restrict its ability to produce, market, manufacture, or distribute products, nor does it necessitate a recall or prevent the pursuit of 510(k) clearance for new products. Despite the seriousness of the FDA's concerns, DexCom asserted that it does not expect a material impact on its manufacturing capacity or its previously issued fiscal year 2025 revenue guidance. The company is actively preparing a response to the warning letter and has already submitted responses to the Form 483. While DexCom is committed to corrective actions and updates to the FDA, it cannot guarantee the FDA's satisfaction with its response or provide an estimated timeline for resolution, acknowledging that further regulatory action remains a possibility.
Key Highlights
- 1DexCom received an FDA warning letter on March 4, 2025, citing manufacturing and quality management system deficiencies.
- 2The warning letter resulted from inspections at San Diego and Mesa facilities and prior Form 483 observations.
- 3The FDA warning letter does NOT restrict product production, marketing, distribution, or the ability to seek 510(k) clearance.
- 4No product recalls are required by the FDA warning letter.
- 5DexCom expects no material impact on its manufacturing capacity.
- 6The company anticipates no material impact on its previously issued fiscal year 2025 revenue guidance.
- 7DexCom is actively preparing a response to the warning letter and implementing corrective actions.